NDC 66406-0203-00: Eslicarbazepine Acetate 600 mg Tablet, 28,571-count
This is a package of 28,571 tablets of Eslicarbazepine Acetate 600 mg Tablet from Patheon Inc., first listed with the FDA Apr 2014 and currently FDA-listed. It is this product's only package size.
NDC database record
One package, one record: these facts belong to NDC 66406-0203-0 alone.
- Record
- FDA NDC Directory package listing · Drug for further processing
- Code segments
- 66406 labeler · 0203 product · 0 package
- Package marketed since
- Apr 7, 2014
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 6640602030 2
- FDA record last changed
- Oct 22, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
- It treats partial-onset seizures, which start in one area of the brain, in people 4 years and older. It's sold as Aptiom and as generic eslicarbazepine acetate tablets.
- Take it by mouth once a day, with or without food. You can swallow the tablet whole or crush it. Your doctor will usually raise the dose gradually, so follow your prescription clos...
- No. Stopping suddenly can make seizures more frequent and can even cause a prolonged, dangerous seizure. If you need to stop, your prescriber will lower the dose gradually.
- Dizziness and sleepiness are common, especially when starting or raising the dose. It can also cause vision changes and trouble with balance or thinking. Use caution with driving o...
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Eslicarbazepine Acetate — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 66406-0203-00 You're viewing this Main listing | 28571 TABLET in 1 CONTAINER | — | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Eslicarbazepine Acetate 600 mg 67877-0587-60 | Ascend | 60 tablets | $1.618 | AB | Availability likely | — |
| Eslicarbazepine Acetate 600 mg 43598-0686-60 | Dr.Reddys | 60 tablets | $1.618 | AB | Availability likely | — |
| Eslicarbazepine Acetate 600 mg 60505-4660-06 | Apotex | 60 tablets | $1.618 | AB | Availability likely | — |
| Eslicarbazepine Acetate 600 mg 68180-0292-07 | Lupin | 60 tablets | $1.618 | AB | Availability likely | — |
| Eslicarbazepine Acetate 600 mg 59651-0535-60 | Aurobindo | 60 tablets | $1.618 | AB | Availability likely | — |
| Aptiom 600 mg 63402-0206-28 | Sumitomo | 28 tablets | — | AB | FDA listed | — |
| Eslicarbazepine acetate 600 mg 13668-0540-05 | Torrent | 500 tablets | — | AB | FDA listed | — |
| Eslicarbazepine Acetate 600 mg 59746-0719-05 | Jubilant | 500 tablets | — | AB | FDA listed | — |
| Eslicarbazepine Acetate 600 mgthis 66406-0203-00 | Patheon | 28571 tablets | — | — | FDA listed | — |
| Eslicarbazepine acetate 600 mg 31722-0430-32 | Camber | 100 tablets | — | AB | FDA listed | — |
| Eslicarbazepine Acetate 600 mg 51407-0781-60 | Golden | 60 tablets | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Eslicarbazepine inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Patheon Inc. labeler code 66406
- Famotidine 10 mg Tablet, Film Coated NDC 66406-0100-0
- Famotidine 20 mg Tablet, Film Coated NDC 66406-0101-1
- emtricitabine and tenofovir disoproxil fumarate 200 mg; 300 mg Tablet, Film Coated NDC 66406-0102-0
- Tenofovir Disoproxil Fumarate 300 mg Tablet, Coated NDC 66406-0103-0
- colesevelam hydrochloride 625 mg Tablet, Film Coated NDC 66406-0106-0
- posaconazole 40 mg/mL Suspension NDC 66406-0200-0
- Eslicarbazepine Acetate 800 mg Tablet NDC 66406-0204-0
- tedizolid phosphate 200 mg Tablet, Coated NDC 66406-0206-1
- EMTRICITABINE 10 mg/mL Solution NDC 66406-0209-0
- dextromethrophan hydrobromide and quinidine sulfate 20 mg; 10 mg Capsule, Gelatin Coated NDC 66406-0211-0
- methylnaltrexone bromide 150 mg Tablet, Film Coated NDC 66406-0219-1
- Eslicarbazepine Acetate 200 mg Tablet NDC 66406-0222-0
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full FDA label FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Patheon Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |